Ignite Creation Date:
2024-05-05 @ 12:00 PM
Last Modification Date:
2024-10-26 @ 9:18 AM
Study NCT ID:
NCT00200512
Status:
COMPLETED
Last Update Posted:
2005-12-16
First Post:
2005-09-13
Brief Title:
Continued Efficacy of Apomorphine After Previous Exposure of at Least Three Months
Sponsor:
Mylan Bertek Pharmaceuticals
Organization:
Mylan Bertek Pharmaceuticals
Study Overview
Official Title:
A Prospective Randomized Placebo-Controlled Crossover Study of the Safety and Effectiveness of Subcutaneous Injections of Apomorphine in the Treatment of Off Episodes in Patients With OnOff or Wearing Off Effects Associated With Late Stage Parkinsons Disease
Status:
COMPLETED
Status Verified Date:
2000-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The objective of this study was to measure the continued efficacy of apomorphine after previous exposure of at least three months duration
Detailed Description:
This was a prospective double-blind randomized placebo-controlled crossover desigh multicenter study of the safety and effectiveness of subcutaneous apomorphine treatment Patients received both apomorphine and placebo in a randomized double-blind fashion
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None